BioSpace News Archive

Proteona today announced that Twist Bioscience Corporation (Nasdaq: TWST) will join the international alliance led by Proteona to develop neutralizing antibody therapy against COVID-19 for vulnerable immunocompromised patients. Utilizing the highly parallel silicon-based DNA synthesis platform, Twist has the ability to manufacture millions of oligos of different lengths with industry leading accuracy. This c

Agilent Technologies Inc. (NYSE: A) today announced two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system. Both deliver even faster detection of target compounds providing customers increased sample throughput and reduc

Total antibody test has demonstrated 100 percent sensitivity and 99.8 percent specificity in identifying SARS-CoV-2 antibodies. The test detects the antibodies believed to neutralize the SARS-CoV-2 virus; specifically targeting antibodies that attach to a spike protein on the surface of the virus. The test is available on the company’s high-throughput analyzers that can deliver up to 440 tests/hour 1 and report results in as few as 10 minut

ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in a registered direct offering, 348,000 shares of ARCA’s common stock, at a purchase price of $9.00 per

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that sulopenem did not achieve statistical non-inferiority relative to ertapenem in its SU lopenem for R esistant E nterobacteriaceae (SURE) 2 clinical trial in complicated

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate apabetalone’s impact on COVID-19 in both a preclinical and clinical setting. A first step will be to investigate whether apabetalone treatment of human cells susceptible to 2019 novel coronavirus (2019-nCoV) infection will impact the replication cycle of the virus. Initial work – undertaken in an ap

ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ: ANIP) announced today that it continues to make progress toward addressing items identified in the Refusal to File letter received from the FDA relating to its Cortrophin® Gel sNDA filing. “The most efficient path forward is to concentrate efforts on the preparation of the resubmission

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and Ont

Connecting with patients to participate in device tracking enables them to be contacted in the event of a safety issue There is no additional safety information being communicated beyond the original July 2019 BIOCELL® recall [01-June-2020] IRVINE, Calif. , June 1, 2020 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is initiating a new di

June 1, 2020 12:30 UTC - First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX ® , potentially giving Mylan access to 14 indications upon approval - - $30 million milestone payable to Revance from Mylan -